Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Open accessThe DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
Abstract
Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory immune-mediated disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and dactylitis), generally occurs in patients with psoriasis. PsA is also associated with uveitis and inflammatory bowel disease (Crohn’s disease and ulcerative colitis). To capture these manifestations as well as the associated comorbidities, and to recognize their underlining common pathogenesis, the name of psoriatic disease was coined. The pathogenesis of PsA is complex and multifaceted, with an interplay of genetic predisposition, triggering environmental factors, and activation of the innate and adaptive immune system, although autoinflammation has also been implicated. Research has identified several immune-inflammatory pathways defined by cytokines (IL-23/IL-17, TNF), leading to the development of efficacious therapeutic targets. However, heterogeneous responses to these drugs occur in different patients and in the different tissues involved, resulting in a challenge to the global management of the disease. Therefore, more translational research is necessary in order to identify new targets and improve current disease outcomes. Hopefully, this may become a reality through the integration of different omics technologies that allow better understanding of the relevant cellular and molecular players of the different tissues and manifestations of the disease. In this narrative review, we aim to provide an updated overview of the pathophysiology, including the latest findings from multiomics studies, and to describe current targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370 · cited 3×
“PD4 inhibition promotes an increase in intracellular cyclic AMP [109], which prevents the synthesis of proinflammatory cytokines, such as TNF [110], and elevates anti-inflammatory cytokines (IL-10) [111].”
BackgroundRole of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385 · cited 1×
“The interaction between the microbiome and the immune system is responsible for many immunoregulatory mechanisms, and dysbiosis leads to alterations in barrier permeability and the consequent activation of the immune system and secretion of proinflammatory cytokines destabilize the junctions between epithelial cells a…”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“The interaction between the microbiome and the immune system is responsible for many immunoregulatory mechanisms, and dysbiosis leads to alterations in barrier permeability and the consequent activation of the immune system and secretion of proinflammatory cytokines destabilize the junctions between epithelial cells a…”
BackgroundBoehncke, W.-H., & Schön, M. P. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61909-7 · Cited by 2,542
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109927 · Cited by 1,816 · cited 17×
“Regarding safety, the ORAL Surveillance study found that patients with RA treated with TOF had an increased risk of cardiovascular events compared with those treated with TNFi [170].”
BackgroundInfluentialHueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547 · cited 12×
“The incidence of herpes zoster (HZ) was higher in both RCT compared with PBO.”
BackgroundInfluentialRitchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1505557 · Cited by 1,404 · cited 1×
“Roughly up to 30% of patients with PsO may develop psoriatic arthritis (PsA), especially those with severe psoriasis or nail or scalp involvement [2,3].”
BackgroundIL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C.-C., Sathe, M., Grein, J., Gorman, D. M., Bowman, E. P., McClanahan, T. K., Yearley, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2817 · Cited by 1,060 · cited 1×
“On the other hand, IL-23-dependent IL-22 can induce phosphorylation of STAT3 in osteoblasts at enthesis sites, leading to bone formation [82].”
BackgroundGossec, L., Baraliakos, X., Kerschbaumer, A., de Wit, M. P. T., McInnes, I. B., Dougados, M., Primdahl, J., McGonagle, D. G., Aletaha, D., Balanescu, A. R., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217159 · Cited by 1,043 · cited 4×
“Both European League Against Rheumatism (EULAR) and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendation guidelines recommend the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) as first-line treatment, followed by apremilast, biologica…”
BackgroundInfluentialSecukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029 · cited 1×
“This lack of response was unexpected, since RCTs of IL-17i have positive outcomes in the same disease [144,145].”
ResultMcInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
The 3 major types of innate and adaptive cell-mediated effector immunity
Annunziato, F., Romagnani, C., & Romagnani, S. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.001 · Cited by 818 · cited 1×
“In healthy conditions, type 3 innate lymphocytes (ILC3) are implicated in gut homeostasis, as IL-23-independent IL-17A is protective in the gut by promoting epithelial cell junctions, whereas IL-23-dependent IL-17 is pathogenic [53].”
BackgroundMcInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807 · cited 2×
“This will ultimately improve the quality of life for those living with PsA or at risk of developing it [131].”
BackgroundNograles, K. E., Zaba, L. C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., Khatcherian, A., Gonzalez, J., Pierson, K. C., White, T. R., et al. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08769.x · Cited by 804
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
Papp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C., Stevens, R. M., Day, R. M., Gordon, K. B., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.03.049 · Cited by 678
Alinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., Gottlieb, A. B., Gisondi, P., Wu, J. J., Thyssen, J. P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.027 · Cited by 673
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204655 · Cited by 662
Coates, L. C., Soriano, E. R., Corp, N., Bertheussen, H., Callis Duffin, K., Campanholo, C. B., Chau, J., Eder, L., Fernández-Ávila, D. G., FitzGerald, O., et al. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00798-0 · Cited by 627 · cited 2×
“Both European League Against Rheumatism (EULAR) and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendation guidelines recommend the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) as first-line treatment, followed by apremilast, biologica…”
BackgroundFunctionally distinct disease-associated fibroblast subsets in rheumatoid arthritis
Mizoguchi, F., Slowikowski, K., Wei, K., Marshall, J. L., Rao, D. A., Chang, S. K., Nguyen, H. N., Noss, E. H., Turner, J. D., Earp, B. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02892-y · Cited by 596 · cited 1×
“These fibroblasts are proliferative, secrete proinflammatory cytokines, and exhibit an in vitro phenotype characteristic of invasive cells [103].”
BackgroundEpidemiology of psoriatic arthritis in the population of the United States
Gelfand, J. M., Gladman, D. D., Mease, P. J., Smith, N., Margolis, D. J., Nijsten, T., Stern, R. S., Feldman, S. R., & Rolstad, T. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.03.046 · Cited by 596
Mease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., Lin, C.-Y., Braun, D. K., Lee, C. H., & Gladman, D. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209709 · Cited by 580 · cited 1×
“Like SEC, IXE has been shown to be superior to PBO in ACR responses, inhibition of radiographic progression, and other clinical domains, in both TNFi refractory populations and naïve patients [157,158].”
MethodThe pathogenesis of psoriatic arthritis
Veale, D. J., & Fearon, U. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30830-4 · Cited by 576 · cited 1×
“Likewise, TGFß and IL-6 induce the expression of IL-23R, promoting the response to IL-23 [77], which is pathogenic [78].”
BackgroundTofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Mease, P., Hall, S., FitzGerald, O., van der Heijde, D., Merola, J. F., Avila-Zapata, F., Cieślak, D., Graham, D., Wang, C., Menon, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615975 · Cited by 571 · cited 17×
“Regarding safety, the ORAL Surveillance study found that patients with RA treated with TOF had an increased risk of cardiovascular events compared with those treated with TNFi [170].”
BackgroundInfluentialTofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Gladman, D., Rigby, W., Azevedo, V. F., Behrens, F., Blanco, R., Kaszuba, A., Kudlacz, E., Wang, C., Menon, S., Hendrikx, T., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615977 · Cited by 510 · cited 17×
“Regarding safety, the ORAL Surveillance study found that patients with RA treated with TOF had an increased risk of cardiovascular events compared with those treated with TNFi [170].”
BackgroundInfluentialMease, P. J., Fleischmann, R., Deodhar, A. A., Wollenhaupt, J., Khraishi, M. M., Kielar, D., Woltering, F., Stach, C. M., Hoepken, B., Arledge, T., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203696 · Cited by 485 · cited 17×
“The KEEPsAKE trials in patients naïve to and with previous biological therapy showed that significantly more patients treated with RZK achieved an ACR 20 response at week 24 than PBO [137,138].”
InfluentialPaul, C., Cather, J., Gooderham, M., Poulin, Y., Mrowietz, U., Ferrandiz, C., Crowley, J., Hu, C., Stevens, R. M., Shah, K., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14164 · Cited by 484
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
Schafer, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.001 · Cited by 439 · cited 3×
“PD4 inhibition promotes an increase in intracellular cyclic AMP [109], which prevents the synthesis of proinflammatory cytokines, such as TNF [110], and elevates anti-inflammatory cytokines (IL-10) [111].”
BackgroundNash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31429-0 · Cited by 405 · cited 1×
“Like SEC, IXE has been shown to be superior to PBO in ACR responses, inhibition of radiographic progression, and other clinical domains, in both TNFi refractory populations and naïve patients [157,158].”
MethodEpithelial Toll-like receptors and their role in gut homeostasis and disease
Burgueño, J. F., & Abreu, M. T. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0261-4 · Cited by 395
Baeten, D., Østergaard, M., Wei, J. C.-C., Sieper, J., Järvinen, P., Tam, L.-S., Salvarani, C., Kim, T.-H., Solinger, A., Datsenko, Y., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213328 · Cited by 390 · cited 3×
“All drugs neutralizing IL-23 (GSK, RZK, and UST) have failed to show effectiveness in axial spondyloarthritis (axSpA) in RCTs [142,143].”
BackgroundTargan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383 · cited 12×
“The incidence of herpes zoster (HZ) was higher in both RCT compared with PBO.”
BackgroundInfluentialvan der Heijde, D., Cheng-Chung Wei, J., Dougados, M., Mease, P., Deodhar, A., Maksymowych, W. P., Van den Bosch, F., Sieper, J., Tomita, T., Landewé, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31946-9 · Cited by 370
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637829 · Cited by 360 · cited 1×
“On the other hand, a variety of innate cells, including MAIT, ILC3, iNKT, and γδ T cells, can produce IL-17 in an IL-23-independent manner [146,147], implicating them in disease pathogenesis.”
BackgroundMease, P. J., Rahman, P., Gottlieb, A. B., Kollmeier, A. P., Hsia, E. C., Xu, X. L., Sheng, S., Agarwal, P., Zhou, B., Zhuang, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30263-4 · Cited by 355 · cited 17×
“The KEEPsAKE trials in patients naïve to and with previous biological therapy showed that significantly more patients treated with RZK achieved an ACR 20 response at week 24 than PBO [137,138].”
BackgroundInfluentialTraves, P. G., Murray, B., Campigotto, F., Galien, R., Meng, A., & Di Paolo, J. A. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219012 · Cited by 350 · cited 1×
“These molecules interact with various members of the signal transducers and activators of transcription (STAT) family to modulate gene transcription downstream of a variety of cell surface cytokine and growth factor receptors [167].”
BackgroundMitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., & Harada, M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23447 · Cited by 346
Ciccia, F., Guggino, G., Rizzo, A., Alessandro, R., Luchetti, M. M., Milling, S., Saieva, L., Cypers, H., Stampone, T., Di Benedetto, P., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210000 · Cited by 338 · cited 1×
“Additionally, dysbiosis in patients with SpA can increase zonulin, increasing the permeability of the intestinal epithelium and imprinting Th9 cells to migrate to the joint [55].”
BackgroundRuiz de Morales, J. M. G., Puig, L., Daudén, E., Cañete, J. D., Pablos, J. L., Martín, A. O., Juanatey, C. G., Adán, A., Montalbán, X., Borruel, N., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102429 · Cited by 338
Self-citationMechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Levin, A. D., Wildenberg, M. E., & van den Brink, G. R. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw053 · Cited by 336 · cited 3×
“However, ETN is less effective compared to monoclonal antibody TNFi (IFX, ADA, GOL, CZP) in the treatment of extra-musculoskeletal inflammatory manifestations associated with PsA, such as uveitis or IBD [124,125].”
BackgroundDeodhar, A., Gensler, L. S., Sieper, J., Clark, M., Calderon, C., Wang, Y., Zhou, Y., Leu, J. H., Campbell, K., Sweet, K., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40728 · Cited by 334 · cited 3×
“All drugs neutralizing IL-23 (GSK, RZK, and UST) have failed to show effectiveness in axial spondyloarthritis (axSpA) in RCTs [142,143].”
BackgroundHumby, F., Durez, P., Buch, M. H., Lewis, M. J., Rizvi, H., Rivellese, F., Nerviani, A., Giorli, G., Mahto, A., Montecucco, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32341-2 · Cited by 329 · cited 1×
“Although there is still much to learn about the local changes in RA and PsA synovial tissue, the progress achieved in RA by the new designs of clinical trials driven by molecular pathology in RA is impressive [180,181], and could be a model for PsA, taking into account the heterogeneity of tissues and clinical domains…”
BackgroundSelf-citationStuart, P. E., Nair, R. P., Tsoi, L. C., Tejasvi, T., Das, S., Kang, H. M., Ellinghaus, E., Chandran, V., Callis-Duffin, K., Ike, R., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.10.019 · Cited by 319 · cited 3×
“Genetic studies have found risk factors associated with the transition to PsA in patients with PsO [8].”
BackgroundMease, P. J., Smolen, J. S., Behrens, F., Nash, P. T., Leage, S. L., Li, L., Tahir, H., Gooderham, M., Krishnan, E., Liu‐Seifert, H., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215386 · Cited by 319 · cited 1×
“In the head-to-head clinical trial, IXE was superior to ADA in achieving the compose primary endpoint of ACR50 and a 100% improvement in the PASI 100 response at week 24, but without significant differences in the clinical musculoskeletal domains at the end of the study [159].”
MethodMinozzi, S., Bonovas, S., Lytras, T., Pecoraro, V., González-Lorenzo, M., Bastiampillai, A. J., Gabrielli, E. M., Lonati, A. C., Moja, L., Cinquini, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1240783 · Cited by 308 · cited 1×
“Due to the safety protocols and guidelines implemented after the introduction of TNFi in the clinic, the current management of these drugs is safe in the short and long term [127,128].”
BackgroundMease, P., van der Heijde, D., Landewé, R., Mpofu, S., Rahman, P., Tahir, H., Singhal, A., Boettcher, E., Navarra, S., Meiser, K., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212687 · Cited by 303
Rivellese, F., Surace, A. E. A., Goldmann, K., Sciacca, E., Çubuk, C., Giorli, G., John, C. R., Nerviani, A., Fossati-Jimack, L., Thorborn, G., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01789-0 · Cited by 294 · cited 1×
“Although there is still much to learn about the local changes in RA and PsA synovial tissue, the progress achieved in RA by the new designs of clinical trials driven by molecular pathology in RA is impressive [180,181], and could be a model for PsA, taking into account the heterogeneity of tissues and clinical domains…”
BackgroundSelf-citationSingh, S., Facciorusso, A., Singh, A. G., Casteele, N. V., Zarrinpar, A., Prokop, L. J., Grunvald, E. L., Curtis, J. R., & Sandborn, W. J. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195123 · Cited by 293 · cited 1×
“Therefore, the link between obesity and PsA provides a potential opportunity to reduce the occurrence of PsA and improve its management by encouraging a reduction in weight, a modifiable risk factor [65].”
BackgroundMenon, B., Gullick, N. J., Walter, G. J., Rajasekhar, M., Garrood, T., Evans, H. G., Taams, L. S., & Kirkham, B. W. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38376 · Cited by 293 · cited 2×
“However, only IL-17+CD8+ T cells correlated with disease activity and joint damage progression in patients with PsA [76].”
BackgroundEdwards, C. J., Blanco, F. J., Crowley, J., Birbara, C. A., Jaworski, J., Aelion, J., Stevens, R. M., Vessey, A., Zhan, X., & Bird, P. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207963 · Cited by 287
Kruithof, E., Baeten, D., Rycke, L. D., Vandooren, B., Foell, D., Roth, J., Cañete, J. D. D., Boots, A. M. H., VEYS, E. M., & Keyser, F. D. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1698 · Cited by 286
Self-citationMcInnes, I. B., Behrens, F., Mease, P. J., Kavanaugh, A., Ritchlin, C., Nash, P., Masmitja, J. G., Goupille, P., Korotaeva, T., Gottlieb, A. B., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30564-x · Cited by 279
Kenna, T. J., Davidson, S. I., Duan, R., Bradbury, L. A., McFarlane, J., Smith, M., Weedon, H., Street, S., Thomas, R., Thomas, G. P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.33507 · Cited by 262 · cited 1×
“On the other hand, a variety of innate cells, including MAIT, ILC3, iNKT, and γδ T cells, can produce IL-17 in an IL-23-independent manner [146,147], implicating them in disease pathogenesis.”
BackgroundMcGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J., & Moots, R. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215356 · Cited by 254 · cited 1×
“Furthermore, differences at the sources and signaling pathways of IL-17A and IL-17F in different stages of inflammation and through different tissues indicate that IL-17A and IL-17F contribute independently to chronic tissue inflammation, having non-redundant roles in axPsA or axSpA [160].”
BackgroundTendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis
Gracey, E., Burssens, A., Cambré, I., Schett, G., Lories, R., McInnes, I. B., Asahara, H., & Elewaut, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0364-x · Cited by 252 · cited 1×
“The role of mechanical stress in ‘overuse’ injuries, such as tendinopathy, has long been known, but mechanical stress is now also emerging as a possible trigger for some forms of chronic inflammatory arthritis, including psoriatic arthritis [57].”
BackgroundMease, P. J., Deodhar, A. A., van der Heijde, D. M. F. M., Behrens, F., Kivitz, A., Neal, J., Kim, J., Singhal, S., Nowak, M., & Banerjee, S. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221664 · Cited by 248 · cited 1×
“No thromboembolic events or HZ were found [176].”
BackgroundAutoinflammation and autoimmunity across rheumatic and musculoskeletal diseases
Szekanecz, Z., McInnes, I. B., Schett, G., Szamosi, S., Benkő, S., & Szűcs, G. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00652-9 · Cited by 241 · cited 1×
“PsO and PsA share multiple genetic risk variants related to innate, adaptive immune, and autoinflammatory pathways [9].”
BackgroundUpadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Mease, P. J., Lertratanakul, A., Anderson, J. K., Papp, K., Van den Bosch, F., Tsuji, S., Dokoupilova, E., Keiserman, M., Wang, X., Zhong, S., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218870 · Cited by 239 · cited 1×
“44% with 15 and 30 mg/day, respectively) [172].”
Li, R., Sun, J., Ren, L.-M., Wang, H.-Y., Liu, W.-H., Zhang, X.-W., Chen, S., Mu, R., He, J., Zhao, Y., et al. (2012) · Rheumatology · doi:10.1093/rheumatology/ker370 · Cited by 232
Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis
Scotti, L., Franchi, M., Marchesoni, A., & Corrao, G. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.01.003 · Cited by 221 · cited 1×
“The incidence of PsA has been estimated in a meta-analysis of 83 for every 100,000 PY (95% CI, 41–167 every 100,000 person-years) [19].”
BackgroundFine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes
Okada, Y., Han, B., Tsoi, L. C., Stuart, P. E., Ellinghaus, E., Tejasvi, T., Chandran, V., Pellett, F., Pollock, R., Bowcock, A. M., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.07.002 · Cited by 215 · cited 1×
“Fine mapping of the MHC region showed that the risk heterogeneity between PsA and PsO might be driven by HLA-B amino acid at position 45, specifically glutamic acid (Glu), which is present in classical HL-B alleles associated with PsA [41].”
BackgroundCutolo, M., Myerson, G. E., Fleischmann, R. M., Lioté, F., Díaz-González, F., Van den Bosch, F., Marzo-Ortega, H., Feist, E., Shah, K., Hu, C., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.151376 · Cited by 211
Mease, P., Coates, L. C., Helliwell, P. S., Stanislavchuk, M., Rychlewska-Hanczewska, A., Dudek, A., Abi-Saab, W., Tasset, C., Meuleners, L., Harrison, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32483-8 · Cited by 196 · cited 1×
“Only one patient treated with FIL had a herpes zoster infection [173].”
BackgroundWILSON, F. C., ICEN, M., CROWSON, C. S., McEVOY, M. T., GABRIEL, S. E., & KREMERS, H. M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080691 · Cited by 195 · cited 1×
“However, up to 25% of patients may have a late onset [31].”
BackgroundCambré, I., Gaublomme, D., Burssens, A., Jacques, P., Schryvers, N., De Muynck, A., Meuris, L., Lambrecht, S., Carter, S., de Bleser, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06933-4 · Cited by 194
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis
Gracey, E., Vereecke, L., McGovern, D., Fröhling, M., Schett, G., Danese, S., De Vos, M., Van den Bosch, F., & Elewaut, D. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0454-9 · Cited by 193 · cited 1×
“In patients with spondyloarthritis (SpA), including PsA, it is suggested that ILC3 elevates the levels of IL-17A and IL-22, perpetuating inflammation, and disrupting the intestinal barrier [54].”
BackgroundFamilial aggregation of psoriatic arthritis
Chandran, V, Schentag, C. T., Brockbank, J. E., Pellett, F. J., Shanmugarajah, S., Toloza, S. M. A., Rahman, P., & Gladman, D. D. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.089367 · Cited by 192
Baeten, D., Demetter, P., Cuvelier, C. A., Kruithof, E., Van Damme, N., De Vos, M., Veys, E. M., & De Keyser, F. (2002) · The Journal of Pathology · doi:10.1002/path.1044 · Cited by 189
Bowes, J., Budu-Aggrey, A., Huffmeier, U., Uebe, S., Steel, K., Hebert, H. L., Wallace, C., Massey, J., Bruce, I. N., Bluett, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms7046 · Cited by 187 · cited 2×
“In addition to the MHC complex, several SNPs in the il23r (IL-23 receptor), TNFAIP3 (TNF-regulated protein A20), and PTPN22 (tyrosine-protein phosphatase non-receptor type 22) genes, as well as an SNP within the 5q31 susceptibility locus, have a stronger association with PsA than with PsO [42].”
BackgroundEigler, A., Siegmund, B., Emmerich, U., Baumann, K. H., Hartmann, G., & Endres, S. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.63.1.101 · Cited by 187
The IL-23/IL-17 axis in psoriatic arthritis
Suzuki, E., Mellins, E. D., Gershwin, M. E., Nestle, F. O., & Adamopoulos, I. E. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.050 · Cited by 186 · cited 2×
“IL-23 is key to the differentiation of Th17 and Th22 cells [81].”
BackgroundPenkava, F., Velasco-Herrera, M. D. C., Young, M. D., Yager, N., Nwosu, L. N., Pratt, A. G., Lara, A. L., Guzzo, C., Maroof, A., Mamanova, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18513-6 · Cited by 186 · cited 1×
“Furthermore, it was shown that these cells are active and pro-inflammatory CD8+ T cells expressing the CXCR3 receptor with its ligands (CXCL9 and CXCL10) are elevated in the SF [106].”
BackgroundMcInnes, I. B., Asahina, A., Coates, L. C., Landewé, R., Merola, J. F., Ritchlin, C. T., Tanaka, Y., Gossec, L., Gottlieb, A. B., Warren, R. B., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02302-9 · Cited by 169
Merola, J. F., Landewé, R., McInnes, I. B., Mease, P. J., Ritchlin, C. T., Tanaka, Y., Asahina, A., Behrens, F., Gladman, D. D., Gossec, L., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02303-0 · Cited by 168
Galbraith, G. M. P. (2009) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(09)79289-5 · Cited by 167
Psoriatic arthritis from a mechanistic perspective
Schett, G., Rahman, P., Ritchlin, C., McInnes, I. B., Elewaut, D., & Scher, J. U. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00776-6 · Cited by 167 · cited 1×
“A predisposing genetic background in the presence of environmental factors, such as infections, microbiota (dysbiosis), obesity, biomechanical stress on the entheses (“deep” Koebner phenomenon) or smoking could activate the innate immune system and precipitate the onset of the disease [36].”
Backgroundon behalf of the FUTURE 3 study group, Nash, P., Mease, P. J., McInnes, I. B., Rahman, P., Ritchlin, C. T., Blanco, R., Dokoupilova, E., Andersson, M., Kajekar, R., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1551-x · Cited by 165
Current Concepts of Psoriasis Immunopathogenesis
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V., & Massari, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111574 · Cited by 163 · cited 1×
“Regulation of the inflammatory cascade requires the response mediated by Treg cells through IL-2 and TGF-ß [84].”
BackgroundPast, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy
Leone, G. M., Mangano, K., Petralia, M. C., Nicoletti, F., & Fagone, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041630 · Cited by 160 · cited 1×
“On the other hand, as a rare AE, cases of the demyelinating disease have been described [129], therefore is not recommended in people with a personal or family history of this neurological disease [130].”
BackgroundDifferences in body mass index among individuals with PsA, psoriasis, RA and the general population
Bhole, V., Choi, H. K., Burns, L. C., Vera‐Kellet, C., Lacaille, D., Gladman, D. D., & Dutz, J. P. (2011) · Rheumatology · doi:10.1093/rheumatology/ker349 · Cited by 159 · cited 9×
“A study using a mixed model method to assess the contribution of single nucleotide polymorphisms (SNP) from genomic wide association studies (GWAS) concluded that both PsO and PsA have a significant hereditary burden, although this is higher in PsO than in PsA [39].”
BackgroundInfluentialRodgers, M., Epstein, D. M., Bojke, L., Yang, H., Craig, D., Fonseca, T., Myers, L., Bruce, I. N., Chalmers, R. J. G., Bujkiewicz, S., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15100 · Cited by 156 · cited 1×
“TNFi is the first line biological therapy recommended by the most treatment guidelines for patients with PsA, proving to be effective in all PsA domains and to inhibit or decrease radiographic progression [5,120].”
BackgroundCañete, J. D. D., Pablos, J. L., Sanmartí, R., Mallofré, C., Marsal, S., Maymó, J., Jordi Gratacós, A., Mezquita, J., Mezquita, C., & Cid, M. C. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20181 · Cited by 154
Self-citationKristensen, L. E., Keiserman, M. W., Papp, K. A., McCasland, L., White, D., Lu, W., Wang, Z., Soliman, A. M., Eldred, A., Barcomb, L. M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221019 · Cited by 152 · cited 17×
“The KEEPsAKE trials in patients naïve to and with previous biological therapy showed that significantly more patients treated with RZK achieved an ACR 20 response at week 24 than PBO [137,138].”
ResultInfluentialGao, W., McGarry, T., Orr, C., McCormick, J., Veale, D. J., & Fearon, U. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207201 · Cited by 149 · cited 5×
“By using the Hsp47 antibody, a marker of lining and sublining SFs, we found a significant increase in sublining SFs in RA compared with PsA [87,88].”
BackgroundInfluentialPattern of demyelination occurring during anti-TNF-α therapy: a French national survey
Séror, R., Richez, C., Sordet, C., Rist, S., Gossec, L., Direz, G., Houvenagel, É., Berthelot, J., Pagnoux, C., Dernis, E., et al. (2013) · Rheumatology · doi:10.1093/rheumatology/kes375 · Cited by 147 · cited 1×
“On the other hand, as a rare AE, cases of the demyelinating disease have been described [129], therefore is not recommended in people with a personal or family history of this neurological disease [130].”
BackgroundObesity and psoriatic arthritis: from pathogenesis to clinical outcome and management
Russolillo, A., Iervolino, S., Peluso, R., Lupoli, R., Minno, A. D., Pappone, N., & Minno, M. N. D. D. (2012) · Rheumatology · doi:10.1093/rheumatology/kes242 · Cited by 146 · cited 2×
“On the other hand, biomechanical stress due to obesity overload could induce an aberrant response to tissue microdamage in entheseal sites, predisposing to local inflammation [64].”
BackgroundComorbidities associated with psoriatic arthritis: Review and update
Perez-Chada, L. M., & Merola, J. F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108397 · Cited by 146
Ectopic lymphoid neogenesis in psoriatic arthritis
Cañete, J. D. D., Santiago, B., Cantaert, T., Sanmartí, R., Palacín, A., Celis, R., Graell, E., Gil-Torregrosa, B., Baeten, D., & Pablos, J. L. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062042 · Cited by 145
Self-citationEder, L., Thavaneswaran, A., Chandran, V., & Gladman, D. D. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201357 · Cited by 140 · cited 2×
“Studies have shown that peripheral PsA is more common in female patients, whereas axial disease is more common in male patients [22,23].”
BackgroundComparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis
Belasco, J., Louie, J. S., Gulati, N., Wei, N., Nograles, K. E., Fuentes‐Duculan, J., Mitsui, H., Suárez‐Fariñas, M., & Krueger, J. G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38995 · Cited by 137 · cited 1×
“PsA-specific genetic variants have been reported [10] and a different pattern of cytokine gene expression has been identified between skin and synovial tissue, explaining differences in the response to biologic therapies between those clinical domains [11].”
BackgroundFraser, A. D., Fearon, U., Billinghurst, R. C., Ionescu, M., Reece, R., Barwick, T. W., Emery, P., Poole, A. R., & Veale, D. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11331 · Cited by 133 · cited 2×
“In addition, studies have shown that PsA synovitis is characterized by macroscopic hypervascularization, resulting in higher vessel density compared with RA, showing the two diseases have different expressions of pro-angiogenic factors, with PsA exhibiting elevated levels of Ang-2 and RA having increased levels of Ang…”
BackgroundIdentification of myeloid cells in the human enthesis as the main source of local IL-23 production
Bridgewood, C., Watad, ., Russell, T., Palmer, T. M., Marzo‐Ortega, H., Khan, A. L., Millner, P. A., Dunsmuir, R. A., Rao, A., Loughenbury, P., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214944 · Cited by 131 · cited 1×
“Interestingly, myeloid cells have been identified as the main source of local IL-23 at the enthesis [60].”
BackgroundThorarensen, S. M., Lu, N., Ogdie, A., Gelfand, J. M., Choi, H. K., & Löve, Þ. J. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209334 · Cited by 125 · cited 1×
“Supporting the clinical relevance of these findings, PsO patients with previous bone trauma had an increased risk of PsA compared with PsO patients without trauma [61].”
ResultAnti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
Frasca, L., Palazzo, R., Chimenti, M. S., Alivernini, S., Tolusso, B., Bui, L., Botti, E., Giunta, A., Bianchi, L., Petricca, L., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01936 · Cited by 124 · cited 1×
“Importantly, both anti-ADAMTS-L5 and anti-LL-37 autoantibody levels were also significantly elevated in PsO patients with PsA compared to those without PsA [96,97].”
BackgroundWoolacott, N. F., Vergel, Y. B., Hawkins, N., Kainth, A., Khadjesari, Z., Misso, K., Light, K., Asseburg, C., Palmer, S., Claxton, K., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10310 · Cited by 114 · cited 1×
“ETN is less immunogenic than the other TNFi and does not require concomitant administration with methotrexate to maintain its long-term effectiveness [122,123].”
BackgroundCoates, L. C., Gossec, L., Theander, E., Bergmans, P., Neuhold, M., Karyekar, C. S., Shawi, M., Noël, W., Schett, G. A., & McInnes, I. B. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220991 · Cited by 114 · cited 1×
“similar to previous data with ustekinumab [136], although a longer follow-up is necessary to confirm it.”
ResultNguyen, U., Zhang, Y., Lu, N., Louie‐Gao, Q., Niu, J., Ogdie, A., Gelfand, J. M., LaValley, M. P., Dubreuil, M., Sparks, J. A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211625 · Cited by 113 · cited 1×
“Smoking has been positively associated with the risk of PsA in the general population [66], although some studies have highlighted a possible paradoxical effect of smoking in patients with psoriasis [67].”
BackgroundGottlieb, A. B., Deodhar, A. A., McInnes, I. B., Baraliakos, X., Reich, K., Schreiber, S., Bao, W., Marfo, K., Richards, H. B., Pricop, L., et al. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.563 · Cited by 107
Punzi, L., Pianon, M., Rossini, P., Schiavon, F., & Gambari, P. F. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.4.226 · Cited by 106 · cited 1×
“In addition, different studies have agreed that the appearance above 60–65 years is associated with more aggressive disease, a higher swollen joints count, higher acute phase reactants, and fatigue [33,34].”
BackgroundAune, D., Snekvik, I., Schlesinger, S., Norat, T., Ríboli, E., & VATTEN, L. J. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0366-z · Cited by 104 · cited 8×
“A study using a mixed model method to assess the contribution of single nucleotide polymorphisms (SNP) from genomic wide association studies (GWAS) concluded that both PsO and PsA have a significant hereditary burden, although this is higher in PsO than in PsA [39].”
BackgroundInfluentialLi, X., Andersen, K. M., Chang, H., Curtis, J. R., & Alexander, G. C. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216102 · Cited by 103 · cited 1×
“Due to the safety protocols and guidelines implemented after the introduction of TNFi in the clinic, the current management of these drugs is safe in the short and long term [127,128].”
BackgroundClaveau, D., Chen, S. L., O’Keefe, S. J., Zaller, D. M., Styhler, A., Liu, S., Huang, Z., Nicholson, D. W., & Mancini, J. A. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.064691 · Cited by 102
TGF-β is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23
Morishima, N., Mizoguchi, I., Takeda, K., Mizuguchi, J., & Yoshimoto, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.140 · Cited by 101 · cited 1×
“Likewise, TGFß and IL-6 induce the expression of IL-23R, promoting the response to IL-23 [77], which is pathogenic [78].”
BackgroundWells, A. F., Edwards, C. J., Kivitz, A., Bird, P., Nguyen, D. D., Paris, M. M., Teng, L. L., & Aelion, J. A. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key032 · Cited by 100
Identification of Novel Autoantibodies Associated With Psoriatic Arthritis
Yuan, Y., Qiu, J., Lin, Z., Li, W., Haley, C. T., Mui, U. N., Ning, J., Tyring, S. K., & Wu, T. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40830 · Cited by 99 · cited 1×
“Importantly, both anti-ADAMTS-L5 and anti-LL-37 autoantibody levels were also significantly elevated in PsO patients with PsA compared to those without PsA [96,97].”
BackgroundBaeten, D., Kruithof, E., Rycke, L. D., Vandooren, B., Wyns, B., Boullart, L., Hoffman, I. E. A., Boots, A. M. H., VEYS, E. M., & Keyser, F. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20476 · Cited by 99 · cited 1×
“The sublining in PsA is similar to RA, but with a greater relative abundance of neutrophils and mast cells [90,91].”
BackgroundFloudas, A., Smith, C. M., Tynan, O., Neto, N. G. B., Krishna, V., Wade, S. M., Hanlon, M. M., Cunningham, C. C., Marzaioli, V., Canavan, M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221761 · Cited by 94 · cited 1×
“These changes show that, although there are similarities between RA and PsA, they are different diseases with different cell subtypes and functions at the local level [104].”
BackgroundSecukinumab failure in Crohn's disease: the yeast connection?
Colombel, J., Sendid, B., Jouault, T., & Poulain, D. (2012) · Gut · doi:10.1136/gutjnl-2012-304154 · Cited by 93 · cited 1×
“Despite their good safety profile, IL-17i is not recommended in patients with IBD since they do not demonstrate efficacy in RCT [164,165] and the possible worsening of the disease [166].”
BackgroundCutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis
Soare, A., Weber, S., Maul, L., Rauber, S., Gheorghiu, A. M., Luber, M., Houssni, I., Kleyer, A., von Pickardt, G., Gado, M., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700596 · Cited by 89 · cited 1×
“In addition, the presence of enthesitis, synovitis, erosions, and bone proliferation assessed by MRI and high-resolution peripheral CT (HR-pQCT) correlated with ILC3 counts in patients with PsA, suggesting the clinically relevant local effects produced by these cells [74].”
BackgroundKivitz, A., Nash, P. T., Tahir, H., Everding, A., Mann, H. F., Kaszuba, A., Pellet, P., Widmer, A., Pricop, L., & Abrams, K. B. (2019) · Rheumatology and Therapy · doi:10.1007/s40744-019-0163-5 · Cited by 89
Mease, P. J., Chohan, S., Garcia-Fructuoso, F. J., Luggen, M. E., Rahman, P., Raychaudhuri, S. P., Chou, R. C., Mendelsohn, A. M., Rozzo, S. J., & Gottlieb, A. B. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219014 · Cited by 86 · cited 1×
“Phase 3 RCTs (INSPIRE-1 and INSPIRE-2) are currently in development [139,140], but positive results are already available from the phase 2 trial in PsA [141].”
BackgroundIncreased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis
Diani, M., Casciano, F., Marongiu, L., Longhi, M., Altomare, A., Pigatto, P. D. M., Secchiero, P., Gambari, R., Banfi, G., Manfredi, A. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47310-5 · Cited by 74 · cited 1×
“In lymph nodes and local tissues, APC activates T lymphocytes (mainly CD8 via MHC HLA-class I), leading to the release of cytokines perpetuating the innate and adaptive type effector responses [75,76].”
BackgroundRodríguez‐Ubreva, J., de la Calle‐Fabregat, C., Li, T., Ciudad, L., Ballestar, M. L., Català‐Moll, F., Morante-Palacios, O., García-Gómez, A., Celis, R., Humby, F., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215355 · Cited by 73
Self-citationImmunopathology of synovitis: from histology to molecular pathways
van de Sande, M. G. H., & Baeten, D. (2015) · Rheumatology · doi:10.1093/rheumatology/kev330 · Cited by 69
Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis
Wade, S. M., Canavan, M., McGarry, T., Low, C., Wade, S. C., Mullan, R. H., Veale, D. J., & Fearon, U. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214138 · Cited by 69 · cited 2×
“ment decisions and the prognosis of PsA patients [107].”
BackgroundHaberman, R. H., MacFarlane, K. A., Catron, S., Samuels, J., Blank, R. B., Toprover, M., Uddin, Z., Hu, J., Castillo, R., Gong, C., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063650 · Cited by 66 · cited 2×
“early eradication of disease, which is ongoing with the PAMPA trial [186].”
BackgroundHoff, M., Gulati, A. M., Romundstad, P., Kavanaugh, A., & Haugeberg, G. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203862 · Cited by 58
Boix-Amorós, A., Badri, M. H., Manasson, J., Blank, R. B., Haberman, R. H., Neimann, A. L., Girija, P. V., Hernández, A. J., Heguy, A., Koralov, S. B., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223389 · Cited by 53 · cited 2×
“These findings show that although the PsO and PsA skin microbiomes share common traits, they also exhibit differences in key taxa that might potentially be used as diagnostic biomarkers, particularly in patients with PsO at risk for disease progression to PsA [56].”
Backgroundde Lemos, L. L. P., Costa, J. D. O., Almeida, A. M., de Oliveira, H. A., Barbosa, M. M., Kakehasi, A. M., & Acúrcio, F. D. A. (2014) · Rheumatology International · doi:10.1007/s00296-014-3006-2 · Cited by 53
Fuentelsaz-Romero, S., Cuervo, A. M., Estrada‐Capetillo, L., Celis, R., Campos, R. G., Ramírez, J., Sastre, S., Samaniego, R., Puig‐Kröger, A., & Cañete, J. D. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613975 · Cited by 52
Self-citationThe Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based Study
Karmacharya, P., Crowson, C. S., Bekele, D. I., Achenbach, S. J., Davis, J. M., Ogdie, A., Duarte‐García, A., Ernste, F. C., Kremers, H. M., Tollefson, M. M., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41741 · Cited by 52 · cited 1×
“There are also discrepancies regarding the prevalence between men and women [20,21].”
BackgroundMavropoulos, Α., Zafiriou, E., Simopoulou, T., Brotis, A. G., Liaskos, C., Roussaki-Schulze, A., Katsiari, C. G., Bogdanos, D. P., & Sakkas, L. I. (2019) · Rheumatology · doi:10.1093/rheumatology/kez204 · Cited by 52 · cited 1×
“Moreover, B cells can produce multiple proinflammatory cytokines and chemokines, and regulatory B cells producing IL-10 (B10 cells) are a critical anti-inflammatory B-cell subset, which are decreased in PsA [100].”
BackgroundMarzaioli, V., Canavan, M., Floudas, A., Flynn, K., Mullan, R. H., Veale, D. J., & Fearon, U. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722349 · Cited by 50 · cited 1×
“TOF specifically targets the development and functional capacity of these DCs [94].”
BackgroundSalvador, G., Sanmartí, R., Garcia-Peiró, A., Rodríguez-Cros, J. R., Muñoz-Gómez, J., & Cañete, J. D. D. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024430 · Cited by 50 · cited 1×
“However, a study confirmed differential p53 expression in the ST of patients with RA and PsA, as well as an association of p53 expression and CD68+ macrophages with joint damage in RA, but not in PsA [92].”
BackgroundSelf-citationThe impact of smoking on prevalence of psoriasis and psoriatic arthritis
Gazel, Ü., Ayan, G., Solmaz, D., Akar, S., & Aydın, S. Z. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa179 · Cited by 43 · cited 1×
“Smoking has been positively associated with the risk of PsA in the general population [66], although some studies have highlighted a possible paradoxical effect of smoking in patients with psoriasis [67].”
BackgroundPhenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy
Najm, A., Goodyear, C. S., McInnes, I. B., & Siebert, S. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00874-5 · Cited by 43
Duruöz, M. T., Gezer, H. H., Nas, K., Kılıç, E., Sargın, B., Kasman, S. A., Alkan, H., Şahin, N., Cengiz, G., Cüzdan, N., et al. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105177 · Cited by 43
Li, Q., Chandran, V., Tsoi, L. C., O’Rielly, D. D., Nair, R. P., Gladman, D. D., Elder, J. T., & Rahman, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-61981-5 · Cited by 39
FAPI PET Opens a New Window to Understanding Immune-Mediated Inflammatory Diseases
Kuwert, T., Schmidkonz, C., Prante, O., Schett, G. A., & Ramming, A. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.263922 · Cited by 36
Navarini, L., Costa, L., Tasso, M., Chimenti, M. S., Currado, D., Fonti, G. L., Ciccozzi, M., Margiotta, D. P. E., Benigno, C., Martino, E. D., et al. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05027-1 · Cited by 32
de la Calle‐Fabregat, C., Niemantsverdriet, E., Cañete, J. D. D., Li, T., Mil, A. H. M. V. D. H., Rodríguez‐Ubreva, J., & Ballestar, E. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41885 · Cited by 32
Self-citationGurke, R., Bendes, A., Bowes, J., Köhm, M., Twyman, R. M., Barton, A. C., Elewaut, D. S., Goodyear, C. S., Hahnefeld, L., Hillenbrand, R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102387 · Cited by 31 · cited 2×
“into assays which are applicable in routine clinical settings [182], the EU IMI2 project HIP-”
BackgroundA deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk
Julià, A., Pinto, J., Jordi Gratacós, A., Queiró, R., Ferrándiz, C., Fonseca, E., Montilla, C. A., Torre‐Alonso, J. C., Puig, L., Venegas, J. J. P., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207190 · Cited by 28
Self-citationUnmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022
Winthrop, K. L., Isaacs, J. D., Mease, P. J., Boumpas, D. T., Baraliakos, X., Gottenberg, J., Siebert, S., Mosca, M., Basu, N., Orange, D. E., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223528 · Cited by 28 · cited 2×
“tissue level, rather than clinical manifestations alone [184].”
BackgroundCharras, A., Garau, J., Hofmann, S. R., Carlsson, E., Cereda, C., Ruß, S., Abraham, S., & Hedrich, C. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.746145 · Cited by 26 · cited 1×
“In another study, peripheral blood CD8+ T cells from 10 PsO and 7 PsA patients concluded that patients with skin psoriasis exhibit DNA methylation patterns in CD8+ T cells that allow differentiation from PsA patients, and reflect the clinical activity of skin disease [49].”
BackgroundPolachek, A., Aljohani, R., Li, S., Ye, J. Y., Chandran, V., & Gladman, D. D. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.08.005 · Cited by 22 · cited 3×
“The HLA-C*06:02 association with PsO is stronger than with PsA and this all le is also associated with a early onset of PsO and a longer time b tween the nset of skin and j int involvement [8].”
BackgroundA “Toll” for Th17 cell expansion
Dávila, E., & Kolls, J. K. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0110057 · Cited by 21 · cited 7×
“Naïve T lymphocytes differentiate into Th17 cells in the presence of TGFß and IL-6, inducing the expression of RORγt and leading to the production of IL-17, IL-22, IL-21, and CCL20, which favor the proliferation of Th17 [73].”
BackgroundInfluentialde la Calle‐Fabregat, C., Rodríguez‐Ubreva, J., Ciudad, L., Ramirez, J. R., Celis, R., Azuaga, A., Cuervo, A. M., Graell, E., Pérez-García, C., Díaz‐Torné, C., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158783 · Cited by 20
Self-citationHIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis
FitzGerald, O., & Pennington, S. R. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00748-w · Cited by 20 · cited 2×
“Although the identification of biomarkers using different omics technologies (Figure 3) is still in the discovery phase, with much work to do to turn the anticipated results of these analyses into assays which are applicable in routine clinical settings [182], the EU IMI2 project HIPPOCRATES represents an exciting opp…”
BackgroundDNA methylation markers in peripheral blood for psoriatic arthritis
Deng, M., Su, Y., Wu, R., Li, S., Zhu, Y., Tang, G., Shi, X., Zhou, T., Zhao, M., & Lu, Q. (2022) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2022.11.001 · Cited by 19 · cited 1×
“One study showed that the differentially methylated sites in peripheral blood can distinguish PsA from PsO, suggesting that DNA methylation is a potential predictive biomarker for PsA [48].”
BackgroundThree‐year U.S. pharmacovigilance report of brodalumab
Lebwohl, M., Leonardi, C. L., Armstrong, A. W., Rawnsley, N. N., Alexander, B., Goehring, E. L., Kerdel, F. A., & Jacobson, A. A. (2021) · Dermatologic Therapy · doi:10.1111/dth.15105 · Cited by 19 · cited 1×
“It is currently approved only for PsO [163].”
BackgroundArmas‐González, E., Díaz-Martín, A., Domínguez‐Luis, M. J., Arce-Franco, M. T., Herrera-García, A., Hernández-Hernández, V., Bustabad, S., Usategui, A., Pablos, J. L., Cañete, J. D. D., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141577 · Cited by 17
Self-citationThe Potential of OMICs Technologies for the Treatment of Immune-Mediated Inflammatory Diseases
Anchang, C. G., Xu, C., Raimondo, M. G., Atreya, R. N., Maier, A., Schett, G. A., Zaburdaev, V., Rauber, S., & Ramming, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147506 · Cited by 16 · cited 2×
“However, the clinical application of multiomics data poses major challenges, including the joint requirement for expertise and advanced facilities in statistics, biology, and computer sciences, as well as the interpretation and therapeutic actionability of molecular findings [12].”
BackgroundLadehesa-Pineda, L., Castro, R. O., Puche-Larrubia, M. Á., Granados, R. E. M., Dougados, M., Collantes‐Estévez, E., & Medina, C. L. (2022) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2022.152146 · Cited by 14
Patrick, M. T., Stuart, P. E., Raja, K., Chi, S., He, Z., Voorhees, J. J., Tejasvi, T., Gudjonsson, J. E., Kahlenberg, J. M., Chandran, V., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00304 · Cited by 13 · cited 1×
“Variants in IL-12B (IL-23/IL-17 pathway), RUNX1 (CD8-lymphocyte activation and differentiation), and IL-13 genes have been also associated with PsA [42,43].”
BackgroundEffectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study
on behalf of ESPOCAT group, Azuaga, A., Frade‐Sosa, B., Láiz, A. M., Estrada, P., Prior-Español, Á., Horcada, L., Polino, L., Moreno, M., Moragues, C., et al. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05057-9 · Cited by 9
Self-citationRauber, S., Mohammadian, H., Schmidkonz, C., Atzinger, A., Soare, A., Maschauer, S., Treutlein, C., Angeli, M. R., Raimondo, M. G., Xu, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.17.524425 · Cited by 5 · cited 1×
“Although FAP expression levels are comparable between fibroblast subtypes in the joint, the FAP internalization rate correlates with the destructive potential of fibroblasts, and resolving fibroblasts have a lower FAP internalization rate, providing a valuable imaging tool to visualize the transition from joint damage…”
BackgroundSelf-citation
Metadata
- Authors
- Azuaga, A. B., Ramírez, J., & Cañete, J. D.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-03-03
- Volume
- 24
- Issue
- 5
- Pages
- 4901
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4323044020
- Cited by
- 190
- References
- 147
- FWCI
- 32.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.